SecBot SecBot
6-K ·Filed Jul 9, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001395064-26-000280
Notable filing: 6-K
Actionable Insight • Neutral

Routine governance filing with no new financial data or corporate events. Monitor next quarterly earnings for revenue and earnings trends.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.61
T+0 close · Jul 9, 2026 · via day close
Latest settled
+7.53%
T+60 · $17.86
Vs SPY
+5.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 9 $16.61entry
  2. T+1 · 4mo ago −0.30%α −0.73% · $16.56
  3. T+5 · 4mo ago +0.72%α +0.85% · $16.73
  4. T+20 · 3mo ago +2.47%α +0.23% · $17.02
  5. T+60 · 7w ago +7.53%α +5.89% · $17.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Takeda filed its annual Corporate Governance Report, confirming compliance with all principles of the Corporate Governance Code. The report details board composition (8 of 11 directors are independent external directors, chair is independent), board effectiveness evaluation, and director compensation policy. No material financial or operational updates were disclosed.

Key Facts

  • Company in full compliance with all Corporate Governance Code principles
  • Board comprises 11 directors; 8 are independent external directors (majority); board chair is an independent external director
  • No anti-takeover measures adopted; no parent company or major shareholder above 10%
  • Board effectiveness evaluation concluded the BOD is operating effectively, noting a transition period with CEO succession and director offboarding
  • Director compensation includes performance-based bonuses and long-term incentives (PSUs/RSUs) with clawback policy

Financial Impact

No financial figures reported

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000280
Document: form6k_070926.htm0001395064-26-000280
Document: 0001395064-26-000280-index-headers.html0001395064-26-000280
Document: 0001395064-26-000280-index.html0001395064-26-000280
Document: 0001395064-26-000280.txt0001395064-26-000280

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026